FDA establishment 3018112871, India. Every inspection FDA has posted for the site, with its outcome and cited regulations, and the shipments FDA refused at the border.
FDA has posted no inspections for this site.
| Product | Charges | Latest |
|---|---|---|
| ESCITALOPRAM OXALATEDrugs · 61NDA83 | Oct 23, 2026 | |
| SOLIFENACIN SUCCINATE (ANTI-CHOLINERGIC)Drugs · 61KCB72 | Aug 6, 2026 | |
| CLONAZEPAM (ANTI-CONVULSANT)Drugs · 61MCB06 | Jul 14, 20262 lines | |
| AMITRAZ (ANTIPARASITIC)Drugs · 60ZCB03 | Jul 14, 2026 | |
| ESCITALOPRAM OXALATEDrugs · 61NDB83 | Jul 14, 2026 | |
| RIFAXIMIN (A-BACTERIAL PT. I) (NOT ANTIBIOTIC)Drugs · 61FCA63 | Jan 15, 2026 | |
| ARIPIPRAZOLE (TRANQUILIZER (ANTI-PSYCHOTIC) - PART II)Drugs · 66NCA06 | May 19, 2025 | |
| ANTI-INFLAMMATORY N.E.C.Drugs · 62GCA99 | Dec 10, 2024 |
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm. FDA Data Dashboard and warning letters
India. Every inspection FDA has posted for the site, with its outcome and cited regulations, and the shipments FDA refused at the border.